ATRC Stock - AtriCure, Inc.
Unlock GoAI Insights for ATRC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $465.31M | $399.25M | $330.38M | $274.33M | $206.53M |
| Gross Profit | $347.52M | $300.37M | $245.94M | $205.86M | $149.31M |
| Gross Margin | 74.7% | 75.2% | 74.4% | 75.0% | 72.3% |
| Operating Income | $-40,013,000 | $-26,683,000 | $-42,669,000 | $55.20M | $-44,233,000 |
| Net Income | $-44,698,000 | $-30,438,000 | $-46,466,000 | $50.20M | $-48,155,000 |
| Net Margin | -9.6% | -7.6% | -14.1% | 18.3% | -23.3% |
| EPS | $-0.95 | $-0.66 | $-1.02 | $1.11 | $-1.14 |
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 17th 2024 | JP Morgan | Resumed | Overweight | $40 |
| April 23rd 2024 | Oppenheimer | Upgrade | Outperform | $32 |
| October 23rd 2023 | JMP Securities | Initiation | Mkt Outperform | $60 |
| September 29th 2023 | UBS | Initiation | Buy | $56 |
Earnings History & Surprises
ATRCEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | $-0.04 | — | — | — |
Q4 2025 | Oct 29, 2025 | $-0.11 | $-0.01 | +90.9% | ✓ BEAT |
Q3 2025 | Jul 29, 2025 | $-0.15 | $-0.02 | +86.7% | ✓ BEAT |
Q2 2025 | Apr 29, 2025 | $-0.25 | $-0.14 | +44.0% | ✓ BEAT |
Q1 2025 | Feb 12, 2025 | $-0.23 | $-0.08 | +65.2% | ✓ BEAT |
Q4 2024 | Oct 29, 2024 | $-0.20 | $-0.17 | +15.0% | ✓ BEAT |
Q3 2024 | Jul 30, 2024 | $-0.15 | $-0.17 | -13.3% | ✗ MISS |
Q2 2024 | May 1, 2024 | $-0.21 | $-0.25 | -19.0% | ✗ MISS |
Q1 2024 | Feb 15, 2024 | $-0.22 | $-0.21 | +4.5% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $-0.30 | $-0.20 | +33.3% | ✓ BEAT |
Q3 2023 | Jul 25, 2023 | $-0.27 | $-0.12 | +55.6% | ✓ BEAT |
Q2 2023 | May 2, 2023 | $-0.34 | $-0.23 | +32.4% | ✓ BEAT |
Q1 2023 | Feb 21, 2023 | $-0.18 | $-0.09 | +50.0% | ✓ BEAT |
Q4 2022 | Nov 1, 2022 | $-0.25 | $-0.27 | -8.0% | ✗ MISS |
Q3 2022 | Aug 2, 2022 | $-0.30 | $-0.32 | -6.7% | ✗ MISS |
Q2 2022 | May 3, 2022 | $-0.27 | $-0.33 | -22.2% | ✗ MISS |
Q1 2022 | Feb 15, 2022 | $-0.26 | $-0.30 | -15.4% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $-0.32 | $2.11 | +759.4% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $-0.33 | $-0.36 | -9.1% | ✗ MISS |
Latest News
JP Morgan Maintains Overweight on AtriCure, Raises Price Target to $48
📈 PositiveAtriCure Treated First Patients With Dual Energy Platform That Integrates Pulsed Field Ablation With Advanced Radiofrequency Ablation
📈 PositiveCanaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $64
📈 PositiveAtriCure Raises FY2025 Adj EPS Guidance from $(0.39)-$(0.34) to $(0.26)-$(0.23) vs $(0.49) Est; Raises FY2025 Sales Guidance from $527.000M-$533.000M to $532.000M-$534.000M vs $530.651M Est
📈 PositiveAtriCure Q3 Adj. EPS $(0.01) Beats $(0.12) Estimate, Sales $134.269M Beat $131.254M Estimate
📈 PositiveAtriCure Enrolls, Treats First Patient In BoxX-NoAF Clinical Study In Orlando, Florida
📈 PositiveFrequently Asked Questions about ATRC
What is ATRC's current stock price?
What is the analyst price target for ATRC?
What sector is AtriCure, Inc. in?
What is ATRC's market cap?
Does ATRC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ATRC for comparison